SLC2A1-AS1在卵巢癌中的表达及临床意义

摘要 目的：探究lncRNA SLC2A1反义RNA 1（SLC2A1 antisense RNA 1，SLC2A1-AS1）在卵巢癌中的表达情况及与卵巢癌患者预后之间的关系，为卵巢癌的诊断和预后提供一种新的生物标志物。方法：通过多个数据库中的卵巢癌样本信息及其实时荧光定量PCR（Real Time Quantitative PCR，RT-qPCR）分别探究SLC2A1-AS1在卵巢癌中的表达情况及其与卵巢癌患者预后之间的关系，通过免疫荧光实验和划痕实验探究SLC2A1-AS1的表达对卵巢癌细胞的增殖和迁移的影响。通过基因本体(Gene ontology，GO)和京都基因与基因组百科全书（Kyoto Encyclopedia of Genes and Genomes，KEGG）分析寻找SLC2A1-AS1影响卵巢癌恶性进程的可能机制。结果：基于多个数据库中的生物信息学分析和RT-qPCR验证发现SLC2A1-AS1在卵巢癌中异常低表达，且SLC2A1-AS1低表达与卵巢癌患者的不良预后密切相关。SLC2A1-AS1过表达可明显抑制卵巢癌细胞的增殖和迁移能力。基于GO和KEGG分析，发现SLC2A1-AS1可能通过调控细胞外基质（extracellular matrix，ECM）组分以及ECM受体的相互作用通路抑制卵巢癌的恶性进程。结论：SLC2A1-AS1可能作为一种关键的潜在的生物标志物抑制着卵巢癌的恶性进展。

Expression and Clinical Significance of SLC2A1-AS1 in Ovarian Cancer

ABSTRACT Objective: To investigate the expression of lncRNA SLC2A1 antisense RNA 1 (SLC2A1-AS1) in ovarian cancer and its relationship with the prognosis of ovarian cancer patients, so as to provide a new biomarker for the diagnosis and prognosis of ovarian cancer. Methods: The expression of SLC2A1-AS1 in ovarian cancer and its relationship with the prognosis of patients with ovarian cancer were investigated by ovarian cancer sample information in multiple databases and real time quantitative PCR (RT-qPCR). The effects of SLC2A1-AS1 expression on the proliferation and migration of ovarian cancer cells were investigated by immunofluorescence assay and scratch test. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) analyses were performed to explore the possible mechanism of SLC2A1-AS1 affecting the malignant progression of ovarian cancer. Results: Based on bioinformatics analysis in multiple databases and RT-qPCR verification, it was found that SLC2A1-AS1 was abnormally low expressed in ovarian cancer, and the low expression of SLC2A1-AS1 was closely related to the poor prognosis of ovarian cancer patients. SLC2A1-AS1 overexpression can significantly inhibit the proliferation and migration of ovarian cancer cells. Based on GO and KEGG analysis, SLC2A1-AS1 may inhibit the malignant progression of ovarian cancer by regulating the interaction pathway of extracellular matrix(ECM) components and ECM receptors. Conclusion: SLC2A1-AS1 may be a key potential biomarker to inhibit the malignant progression of ovarian cancer.